The biotech’s lead asset, AVD-104, failed to beat Astellas’ Izervay at slowing the rate of retina lesion growth, the primary ...

Cell therapy company Link Cell Therapies is launching with $60 million and a mission to develop potent CAR-T therapies that ...

Kyverna Therapeutics looks all the more likely to win the first FDA approval for a CAR-T therapy in an autoimmune disease ...

Lumexa Imaging hauled in $462.5 million during its initial public offering, far exceeding the $200 million the outpatient ...

Less than six months after a series A fundraise, AI drug developer Chai Discovery has brewed up a $130 million series B to ...

Ringside’s phase 3 findings reveal the potential varegacestat has to deliver “best-in-class results in a convenient, ...

Philips has claimed the cardiac artificial intelligence developer SpectraWAVE in a bid to expand the capabilities of its real ...

So continues the rocky path for the drug, which Sanofi picked up in its $3.7 billion buyout of Principia Biopharma back in ...

Fresh off a $153 million series E round, Arthrosi Therapeutics is skipping an IPO route and is instead being bought up for a ...

CMS spending on skin substitutes is rising. New policies are an important first step in reform to ensure patient access and ...

As 2025 closes out, a pair of autoimmune biotechs have eked out separate deals with Big Pharma before year-end, each with a sizeable potential payout down the line. | Seattle’s Adaptive ...

Unmatched expertise in patient recruitment and retentionOne of the critical challenges in clinical trials is patient ...